Rituxan

Latest stories

1d
Boston Globe
Kite cancer treatment notches positive results but questions remaincalled diffuse large B cell lymphoma, or DLBCL. Most DLBCL patients go into rem
Kite cancer treatment notches positive results but questions remain
Boston Globe / Posted yesterday
called diffuse large B cell lymphoma, or DLBCL. Most DLBCL patients go into remission after treatment with the cancer drug Rituxan and a battery of chemotherapy, but about one-third don’t respond to that regimen. It is these patients, who only... Read more
7 related stories
18d
Morningstar
Drug Pricing Power Transcends Politicsendeavor. In Roche's pharmaceutical division, blockbuster cancer biologics acq
Drug Pricing Power Transcends Politics
Morningstar / Posted 18 days ago
endeavor. In Roche's pharmaceutical division, blockbuster cancer biologics acquired with Genentech--including Avastin, Rituxan, and Herceptin--continue to grow quickly as they gain market share in approved indications and garner widened... Read more
20d
Morningstar
Looking for Bargains? Check Out High-Quality Healthcare Stockspharmaceutical segment, Andersen points out that blockbuster cancer biologics a
Looking for Bargains? Check Out High-Quality Healthcare Stocks
Morningstar / Posted 20 days ago
pharmaceutical segment, Andersen points out that blockbuster cancer biologics acquired with Genentech--including Avastin, Rituxan, and Herceptin--continue to grow quickly as they gain market share in approved indications, and they have also gained... Read more
26d
FOX News
Regulators pave way for biosimilar drug breakthroughbacking of biosimilar versions of Remicade is also likely increase the perceive
Regulators pave way for biosimilar drug breakthrough
FOX News / Posted 26 days ago
backing of biosimilar versions of Remicade is also likely increase the perceived risk for Roche's top-selling cancer drugs Rituxan and Herceptin. Roche is trying to protect its existing products by bringing out improved, patented versions of its... Read more
8 related stories
27d
Swissinfo
Novartis Taps Biosimilar Experience in Europe to Snag U.S. Salesby the end of the decade, including versions of Enbrel and Neulasta, AbbVie Inc
Novartis Taps Biosimilar Experience in Europe to Snag U.S. Sales
Swissinfo / Posted 27 days ago
by the end of the decade, including versions of Enbrel and Neulasta, AbbVie Inc.’s Humira and Roche Holding AG’s Rituxan -- biologics that generated about $44 billion in 2015 sales globally, the company said in June. Biosimilars tend to... Read more
8 related stories
29d
Morningstar
Allergan Still Undervaluedface stringent manufacturing, regulatory, and marketing hurdles. The partnershi
Allergan Still Undervalued
Morningstar / Posted 29 days ago
face stringent manufacturing, regulatory, and marketing hurdles. The partnership includes biosimilar versions of Erbitux, Rituxan, Avastin, and Herceptin. Industry Leader in Specialty Markets We think Allergan possesses a wide economic moat.... Read more

People in this news